Increased Rate of Lung Function Decline in Australian Adolescents With Cystic Fibrosis

被引:28
|
作者
Welsh, Liam [1 ,2 ]
Robertson, Colin F. [1 ,2 ]
Ranganathan, Sarath C. [1 ,2 ]
机构
[1] Royal Childrens Hosp, Melbourne, Vic, Australia
[2] Murdoch Childrens Res Inst, Melbourne, Vic, Australia
关键词
cystic fibrosis; lung function; decline; Pseudomonas aeruginosa; RESOLUTION COMPUTED-TOMOGRAPHY; PULMONARY-FUNCTION; CHILDREN; DISEASE; EXACERBATIONS; PROGRESSION; SPIROMETRY; ADULTS;
D O I
10.1002/ppul.22946
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: Though baseline lung function as measured by spirometry in children with cystic fibrosis (CF) has improved, the annual rate of decline has not changed significantly during the critical period of adolescence. The aim of this study was to describe factors associated with longitudinal decline in lung function in a contemporary cohort of children with CF. Methods: Best annual lung function data from children attending the CF service of the Royal Children's Hospital Melbourne were reviewed to determine rate of decline in FEV1 up until time of transfer to an adult center. Mixed models were used to determine the influence of age, sex, genotype, newborn screening, respiratory hospitalization, CF related diabetes mellitus (CFRD), pancreatic insufficiency, Pseudomonas aeruginosa (PsA) infection, and body mass index (BMI) on lung function decline. Results: Longitudinal lung function data (range 5-20 years) were obtained for 98 patients with CF (55 male). Overall, the annual rate of decline in FEV1 % predicted for the entire cohort was 1.4% per annum though the greatest rate of FEV1 decline was seen during adolescence (2.6%). Increasing age, homozygous Delta F508 genotype, CFRD, mucoid PsA infection, pancreatic insufficiency and respiratory hospitalizations were all significant predictors of FEV1 decline. Conclusion: FEV1 declines at its sharpest rate during adolescence even in the presence of newborn screening. Genotype, increasing age, CFRD, PsA infection, pancreatic insufficiency and a greater number of respiratory hospitalizations are all associated with an increased rate of lung function decline in Australian children and adolescents with cystic fibrosis. (C) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:873 / 877
页数:5
相关论文
共 50 条
  • [41] Association of vitamin A status with lung function in children and adolescents with cystic fibrosis
    Loukou, Ioanna
    Moustaki, Maria
    Sardeli, Olympia
    Plyta, Marina
    Katsagoni, Christina N.
    Douros, Konstantinos
    PEDIATRIC INVESTIGATION, 2021, 5 (02) : 125 - 129
  • [42] DENUFOSOL IMPROVED LUNG FUNCTION AND WAS WELL TOLERATED IN ADOLESCENTS WITH CYSTIC FIBROSIS
    Moss, R. B.
    Schaberg, A.
    Tian, W.
    Xue, X.
    Ramsey, B.
    Accurso, F. J.
    PEDIATRIC PULMONOLOGY, 2010, : 310 - 310
  • [43] Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis
    De Boeck, K.
    Vermeulen, F.
    Wanyama, S.
    Thomas, M.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (05) : 1091 - 1095
  • [44] Reduced survival in adult cystic fibrosis despite attenuated lung function decline
    Keating, Claire
    Poor, Arrneen D.
    Liu, Xinhua
    Chiuzan, Codruta
    Backenroth, Daniel
    Zhang, Yuan
    DiMango, Emily
    JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (01) : 78 - 84
  • [45] Risk factors for early lung function decline in young children with Cystic Fibrosis
    Balinotti, Juan
    Chang, Daniel
    Rodriguez, Viviana
    Lubovich, Silvina
    Zaragoza, Silvina
    Escobar, Natalia
    Kofman, Carlos
    Perez, Lucia
    Ardiles, Victoria
    Teper, Alejandro
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [46] A Tool for Predicting Risk of Future Lung Function Decline in Cystic Fibrosis Patients
    Wagener, J.
    VanDevanter, D.
    Pasta, D.
    Elkin, E.
    Jacobs, J.
    Morgan, W.
    Konstan, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [47] Effect of key pharmacological therapies on decline in lung function in adults with cystic fibrosis
    Berinaer, P.
    Chawla, S.
    Ahn, J.
    Tsou, J. A.
    Hidayat, L.
    Benitez, D.
    Rao, A. P.
    PEDIATRIC PULMONOLOGY, 2007, : 333 - 334
  • [48] Pseudomonas aeruginosa type III secretion and lung function decline in cystic fibrosis
    Jain, M.
    Bar-Meir, M.
    King, J.
    Cullina, J.
    Potter, E.
    Powers, C.
    Seshadri, R.
    Yogev, R.
    McColley, S. A.
    PEDIATRIC PULMONOLOGY, 2007, : 316 - 317
  • [49] Predictors of lung function decline in stable non-cystic fibrosis bronchiectasis
    Ringshausen, Felix C.
    de Roux, Andres
    Pletz, Mathias W.
    Bange, Franz-Christoph
    Suhling, Hendrik
    Welte, Tobias
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [50] Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy
    Zhou, Grace C.
    Wang, Ziyun
    Palipana, Anushka K.
    Andrinopoulou, Eleni-Rosalina
    Miranda Afonso, Pedro
    Mcphail, Gary L.
    Siracusa, Christopher M.
    Gecili, Emrah
    Szczesniak, Rhonda D.
    RESPIRATORY RESEARCH, 2024, 25 (01)